Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,340
Distinct drugs
372
Records naming a cancer
982
Dated in the last 12 months
182
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 49 | Sep 22, 2026 |
| EMA | EU | 459 | 245 | 385 | 74 | 18 | Jul 20, 2026 |
Data updated 18 hours agoSource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| — | Pemetrexed | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEMETREXED DISODIUM FOR INJECTION (DIN 02411024) under ATC L01BA04 PEMETREXED. Indications are not published in the… | DIN02411024 | withdrawnsource: Cancelled Pre Marketsince Sep 30, 2024 | health-canada-dpd |
| — | Pemetrexed | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEMETREXED DISODIUM FOR INJECTION (DIN 02411016) under ATC L01BA04 PEMETREXED. Indications are not published in the… | DIN02411016 | withdrawnsource: Cancelled Pre Marketsince Sep 30, 2024 | health-canada-dpd |
| — | Idarubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as IDARUBICIN HYDROCHLORIDE INJECTION (DIN 02410354) under ATC L01DB06 IDARUBICIN. Indications are not published in the… | DIN02410354 | withdrawnsource: Cancelled Pre Marketsince Feb 28, 2022 | health-canada-dpd |
| — | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as GEMCITABINE FOR INJECTION USP (DIN 02409933) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug… | DIN02409933 | approved | health-canada-dpd |
| — | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as GEMCITABINE FOR INJECTION USP (DIN 02409925) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug… | DIN02409925 | approved | health-canada-dpd |
| — | Paclitaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as AJ-PACLITAXEL (DIN 02409712) under ATC L01CD01 PACLITAXEL. Indications are not published in the Drug Product Database… | DIN02409712 | withdrawnsource: Cancelled Pre Marketsince Nov 3, 2015 | health-canada-dpd |
| — | Trametinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as MEKINIST (DIN 02409631) under ATC L01EE01 TRAMETINIB. Indications are not published in the Drug Product Database —… | DIN02409631 | withdrawnsource: Cancelled Pre Marketsince May 15, 2017 | health-canada-dpd |
| — | Epirubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as EPIRUBICIN HYDROCHLORIDE INJECTION (DIN 02409372) under ATC L01DB03 EPIRUBICIN. Indications are not published in the… | DIN02409372 | approved | health-canada-dpd |
| — | Cisplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as PMS-CISPLATIN (DIN 02409194) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product Database… | DIN02409194 | withdrawnsource: Cancelled Pre Marketsince Aug 3, 2017 | health-canada-dpd |
| — | Cisplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as CISPLATIN INJECTION (DIN 02409186) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product… | DIN02409186 | approved | health-canada-dpd |
| — | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as AJ-GEMCITABINE (DIN 02409070) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product… | DIN02409070 | withdrawnsource: Cancelled Pre Marketsince Nov 3, 2015 | health-canada-dpd |
| — | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as AJ-GEMCITABINE (DIN 02409062) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product… | DIN02409062 | withdrawnsource: Cancelled Pre Marketsince Nov 3, 2015 | health-canada-dpd |
| — | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as AJ-GEMCITABINE (DIN 02409054) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product… | DIN02409054 | withdrawnsource: Cancelled Pre Marketsince Nov 3, 2015 | health-canada-dpd |
| — | Fludarabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as AJ-FLUDARABINE (DIN 02409046) under ATC L01BB05 FLUDARABINE. Indications are not published in the Drug Product… | DIN02409046 | withdrawnsource: Cancelled Pre Marketsince Nov 3, 2015 | health-canada-dpd |
| — | Paclitaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as PACLITAXEL INJECTION, USP (DIN 02408074) under ATC L01CD01 PACLITAXEL. Indications are not published in the Drug… | DIN02408074 | withdrawnsource: Cancelled Pre Marketsince Feb 24, 2022 | health-canada-dpd |
| — | Bicalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as MED-BICALUTAMIDE (DIN 02407531) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product… | DIN02407531 | approved | health-canada-dpd |
| — | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as GEMCITABINE FOR INJECTION, USP (DIN 02407299) under ATC L01BC05 GEMCITABINE. Indications are not published in the… | DIN02407299 | withdrawnsource: Cancelled Pre Marketsince May 8, 2017 | health-canada-dpd |
| — | Vinblastine | Health Canada CA | cancer not stated in this record | Marketed in Canada as VINBLASTINE SULFATE INJECTION (DIN 02406675) under ATC L01CA01 VINBLASTINE. Indications are not published in the Drug… | DIN02406675 | withdrawnsource: Cancelled Pre Marketsince Aug 1, 2019 | health-canada-dpd |
| — | Topotecan | Health Canada CA | cancer not stated in this record | Marketed in Canada as PMS-TOPOTECAN (DIN 02406438) under ATC L01CE01 TOPOTECAN. Indications are not published in the Drug Product Database… | DIN02406438 | withdrawnsource: Cancelled Pre Marketsince Jul 31, 2026 | health-canada-dpd |
| — | Fludarabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as FLUDARABINE PHOSPHATE INJECTION (DIN 02406381) under ATC L01BB05 FLUDARABINE. Indications are not published in the… | DIN02406381 | withdrawnsource: Cancelled Pre Marketsince Feb 28, 2022 | health-canada-dpd |
| — | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as ACCEL-LETROZOLE TABLETS USP (DIN 02406330) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug… | DIN02406330 | withdrawnsource: Cancelled Pre Marketsince May 19, 2017 | health-canada-dpd |
| — | Megestrol | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-MEGESTROL (DIN 02405512) under ATC L02AB01 MEGESTROL. Indications are not published in the Drug Product Database… | DIN02405512 | approved | health-canada-dpd |
| — | Megestrol | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-MEGESTROL (DIN 02405504) under ATC L02AB01 MEGESTROL. Indications are not published in the Drug Product Database… | DIN02405504 | approved | health-canada-dpd |
| — | Exemestane | Health Canada CA | cancer not stated in this record | Marketed in Canada as MYLAN-EXEMESTANE (DIN 02405075) under ATC L02BG06 EXEMESTANE. Indications are not published in the Drug Product… | DIN02405075 | withdrawnsource: Cancelled Pre Marketsince Nov 2, 2016 | health-canada-dpd |
| — | Cytarabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as AJ-CYTARABINE (DIN 02404397) under ATC L01BC01 CYTARABINE. Indications are not published in the Drug Product Database… | DIN02404397 | withdrawnsource: Cancelled Pre Marketsince Nov 3, 2015 | health-canada-dpd |
| — | Cytarabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as CYTOSAR (DIN 02403838) under ATC L01BC01 CYTARABINE. Indications are not published in the Drug Product Database — see… | DIN02403838 | approved | health-canada-dpd |
| — | Cytarabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as CYTOSAR (DIN 02403811) under ATC L01BC01 CYTARABINE. Indications are not published in the Drug Product Database — see… | DIN02403811 | approved | health-canada-dpd |
| — | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as GEMCITABINE FOR INJECTION (DIN 02402866) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug… | DIN02402866 | withdrawnsource: Cancelled Pre Marketsince Jan 12, 2022 | health-canada-dpd |
| — | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as GEMCITABINE FOR INJECTION (DIN 02402858) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug… | DIN02402858 | withdrawnsource: Cancelled Pre Marketsince Jan 12, 2022 | health-canada-dpd |
| — | Cytarabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as CYTARABINE INJECTION, MYLAN STD. (DIN 02402203) under ATC L01BC01 CYTARABINE. Indications are not published in the… | DIN02402203 | withdrawnsource: Cancelled Pre Marketsince Feb 24, 2022 | health-canada-dpd |
| — | Bicalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as ACCEL-BICALUTAMIDE TABLETS USP (DIN 02400731) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the… | DIN02400731 | withdrawnsource: Cancelled Pre Marketsince May 19, 2017 | health-canada-dpd |
| — | Doxorubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as DOXORUBICIN HYDROCHLORIDE INJECTION (DIN 02400626) under ATC L01DB01 DOXORUBICIN. Indications are not published in… | DIN02400626 | approved | health-canada-dpd |
| — | Anastrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as ACCEL-ANASTROZOLE TABLETS (DIN 02397692) under ATC L02BG03 ANASTROZOLE. Indications are not published in the Drug… | DIN02397692 | withdrawnsource: Cancelled Pre Marketsince May 9, 2017 | health-canada-dpd |
| — | Vinorelbine | Health Canada CA | cancer not stated in this record | Marketed in Canada as AJ-VINORELBINE (DIN 02396416) under ATC L01CA04 VINORELBINE. Indications are not published in the Drug Product… | DIN02396416 | withdrawnsource: Cancelled Pre Marketsince Nov 3, 2015 | health-canada-dpd |
| — | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as ACT TEMOZOLOMIDE (DIN 02395304) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product… | DIN02395304 | withdrawnsource: Cancelled Pre Marketsince Mar 17, 2021 | health-canada-dpd |
| — | Cytarabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as CYTARABINE INJECTION BP (DIN 02394901) under ATC L01BC01 CYTARABINE. Indications are not published in the Drug… | DIN02394901 | withdrawnsource: Cancelled Pre Marketsince Aug 1, 2019 | health-canada-dpd |
| — | Cisplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as CISPLATIN INJECTION (DIN 02393832) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product… | DIN02393832 | approved | health-canada-dpd |
| — | Topotecan | Health Canada CA | cancer not stated in this record | Marketed in Canada as MYLAN-TOPOTECAN HYDROCHLORIDE FOR INJECTION (DIN 02392798) under ATC L01CE01 TOPOTECAN. Indications are not published… | DIN02392798 | withdrawnsource: Cancelled Pre Marketsince Jun 15, 2018 | health-canada-dpd |
| — | Vinorelbine | Health Canada CA | cancer not stated in this record | Marketed in Canada as VINORELBINE INJECTION, USP (DIN 02392445) under ATC L01CA04 VINORELBINE. Indications are not published in the Drug… | DIN02392445 | withdrawnsource: Cancelled Pre Marketsince Feb 28, 2022 | health-canada-dpd |
| — | Epirubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as EPIRUBICIN HYDROCHLORIDE INJECTION (DIN 02387379) under ATC L01DB03 EPIRUBICIN. Indications are not published in the… | DIN02387379 | withdrawnsource: Cancelled Pre Marketsince Aug 1, 2019 | health-canada-dpd |
| — | Catumaxomab | Health Canada CA | cancer not stated in this record | Marketed in Canada as REMOVAB (DIN 02385732) under ATC L01FX03 CATUMAXOMAB. Indications are not published in the Drug Product Database —… | DIN02385732 | withdrawnsource: Cancelled Pre Marketsince Feb 22, 2018 | health-canada-dpd |
| — | Catumaxomab | Health Canada CA | cancer not stated in this record | Marketed in Canada as REMOVAB (DIN 02385724) under ATC L01FX03 CATUMAXOMAB. Indications are not published in the Drug Product Database —… | DIN02385724 | withdrawnsource: Cancelled Pre Marketsince Feb 22, 2018 | health-canada-dpd |
| — | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as LETROZOLE TABLETS (DIN 02381958) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product… | DIN02381958 | withdrawnsource: Cancelled Pre Marketsince Mar 10, 2023 | health-canada-dpd |
| — | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as METHOTREXATE PF/SA INJECTION (DIN 02377624) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug… | DIN02377624 | withdrawnsource: Cancelled Pre Marketsince Aug 1, 2018 | health-canada-dpd |
| — | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as LETROZOLE SUN (DIN 02375273) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product Database… | DIN02375273 | withdrawnsource: Cancelled Pre Marketsince Jul 11, 2022 | health-canada-dpd |
| — | Bicalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as AG-BICALUTAMIDE (DIN 02374412) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product… | DIN02374412 | withdrawnsource: Cancelled Pre Marketsince Jul 14, 2026 | health-canada-dpd |
| — | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as IPG-LETROZOLE (DIN 02370794) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product Database… | DIN02370794 | approved | health-canada-dpd |
| — | Bleomycin | Health Canada CA | cancer not stated in this record | Marketed in Canada as BLEOMYCIN FOR INJECTION USP (DIN 02367351) under ATC L01DC01 BLEOMYCIN. Indications are not published in the Drug… | DIN02367351 | withdrawnsource: Cancelled Pre Marketsince Aug 1, 2019 | health-canada-dpd |
| — | Bicalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as BICALUTAMIDE TABLETS (DIN 02360098) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product… | DIN02360098 | withdrawnsource: Cancelled Pre Marketsince Mar 10, 2023 | health-canada-dpd |
| — | Exemestane | Health Canada CA | cancer not stated in this record | Marketed in Canada as GD-EXEMESTANE (DIN 02359693) under ATC L02BG06 EXEMESTANE. Indications are not published in the Drug Product Database… | DIN02359693 | withdrawnsource: Cancelled Pre Marketsince Oct 29, 2020 | health-canada-dpd |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.